Hong Kong Pharmaceuticals Stock News

SEHK:142
SEHK:142Food

First Pacific DbVIC Talk To Spotlight Portfolio Risks And Capital Choices

First Pacific (SEHK:142) is scheduled to present at the dbVIC, the Deutsche Bank ADR Virtual Investor Conference. Company leaders plan to engage directly with investors and analysts during the upcoming event. The presentation is expected to highlight First Pacific's diversified operations across Southeast Asia. For you as an investor, this conference appearance is a chance to hear directly from First Pacific's leadership on its core businesses across the region. The group has exposure to...
SEHK:1548
SEHK:1548Life Sciences

Is It Time To Reassess Genscript Biotech (SEHK:1548) After Its Recent Share Price Recovery?

If you are wondering whether Genscript Biotech at HK$13.85 is priced for opportunity or already reflecting the story, this valuation breakdown is designed to give you a clear starting point. The stock has returned 0.7% over the last 7 days, 25.8% over the last 30 days, 8.3% year to date, and 25.2% over 1 year, while the 3 year and 5 year returns sit at 32.8% and 23.1% declines respectively. These mixed returns mean context really matters. Recent company updates, financing decisions,...
SEHK:1919
SEHK:1919Shipping

A Look At COSCO SHIPPING Holdings (SEHK:1919) Valuation After Mixed Recent Share Price Performance

Context for COSCO SHIPPING Holdings after recent performance COSCO SHIPPING Holdings (SEHK:1919) has drawn attention after recent share price moves, with the stock showing mixed returns over the past month and past 3 months, alongside modest annual revenue growth and weaker net income growth. See our latest analysis for COSCO SHIPPING Holdings. At a share price of HK$14.75, COSCO SHIPPING Holdings has seen short term momentum cool after a 10.9% 3 month share price return. However, the 1...
SEHK:1093
SEHK:1093Pharmaceuticals

Assessing CSPC Pharmaceutical Group (SEHK:1093) Valuation After Key PEComa Trial Success

CSPC Pharmaceutical Group (SEHK:1093) has flagged a key product milestone after its subsidiary reported that a Phase Ib/III trial of Sirolimus for Injection in advanced malignant PEComa met its primary efficacy endpoint in China. See our latest analysis for CSPC Pharmaceutical Group. The HB1901 trial news sits alongside a mixed share price picture, with CSPC Pharmaceutical Group’s HK$8.98 latest close coming after a 5.8% year to date share price return but an 8.5% 3 month share price decline,...
SEHK:2883
SEHK:2883Energy Services

Assessing China Oilfield Services (SEHK:2883) Valuation After Mixed First Quarter 2026 Earnings

Why the latest earnings matter for China Oilfield Services (SEHK:2883) China Oilfield Services (SEHK:2883) released first quarter 2026 results with sales of CNY 11,296.31 million and net income of CNY 855.69 million, figures that give investors fresh data to reassess the stock. See our latest analysis for China Oilfield Services. The Q1 earnings announcement, which paired higher sales with slightly lower net income and earnings per share year on year, coincides with a 1-day share price...
SEHK:1024
SEHK:1024Interactive Media and Services

A Look At Kuaishou Technology’s (SEHK:1024) Valuation After Recent Share Price Weakness

Setting the scene for Kuaishou Technology Kuaishou Technology (SEHK:1024) has drawn investor attention after a period of weak share price performance, with the stock showing negative returns over the past month, past 3 months, and year to date. See our latest analysis for Kuaishou Technology. At a latest share price of HK$43.7, Kuaishou’s weak recent momentum, including a 30 day share price return of 17.62% decline and a 1 year total shareholder return of 13.33% decline, points to fading...